A novel method for determining the prognosis of a subject with adenocarcinoma in an organ and to aid in the selection of a specific therapeutic regimen.

Available for licensing and commercial development is a novel method for determining the prognosis of a subject with adenocarcinoma in an organ, such as the lung, and to aid in the selection of a specific therapeutic regimen.  Lung adenocarcinoma (AC) is the predominant histological subtype of lung cancer, which is the leading cause of cancer deaths worldwide. The risk of metastasis remains substantial in AC patients, even when a curative resection of early-stage AC is performed.  The prognosis includes the determination of the likelihood of survival, the likelihood of metastasis, or both.  The method includes quantization of the expression of a plurality of Th1 and Th2 cytokines of interest in the adenocarcinoma and in non-cancerous tissue in the organ.  Altered expression of one or more of the Th1 and Th2 cytokines in the adenocarcinoma as compared to the non-cancerous tissue determines the prognosis for the subject. The method is capable of distinguishing patients with lymph node metastasis versus those with short term survival. Furthermore, methods are provided for evaluating the effectiveness of anti-cancer agents.

 

Applications: 

Prognosis of adenocarcinoma, aid in the selection of specific therapeutic regimens and evaluation of the effectiveness of anti-cancer agents.

 

Early Stage

PCT Application No. PCT/US2007/073637 filed 16 Jul 2007, which published as WO 2008/009028 on 17 Jan 2008; claiming priority to 14 Jul 2006 (HHS Reference No. E-263-2006/1-PCT-01)

 

Inventors: 

Curtis C. Harris, Masahiro Seike, Xin Wei Wang (NCI)

 

 

Licensees Sought: 

Available for non-exclusive or exclusive licensing.